On April 1, 2025 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported its participation in the Jones Las Vegas Healthcare and Technology Innovation Conference, to be held on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada (Press release, Anixa Biosciences, APR 1, 2025, View Source [SID1234651710]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Catelani, President and CFO of Anixa, will deliver a presentation and be available for one-on-one meetings during the conference.

Details of the presentation are as follows:

Event: Jones Healthcare and Technology Innovation Conference
Date: April 9, 2025
Time: 4:30 PM PT
Location: The Venetian Resort
Webcast: View Source

The Jones Healthcare and Technology Innovation Conference will bring together a select group of innovative companies and institutional investors for a two-day event. The conference will be focused on one-on-one (1×1) meetings, fireside chats, panels, presentations, and signature networking events. Organized by Jones, with marketing support from B2i Digital, Inc., the event offers an opportunity for direct dialogue between senior company executives and investors seeking engagement with innovative management teams.

For more information, a list of participating companies and to submit registration requests about the Jones Las Vegas Healthcare and Technology Innovation Conference, visit their B2i Digital Featured Conference page.

On April 1, 2025 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported it has granted equity awards to new non-executive employees who joined the Company (Press release, Abeona Therapeutics, APR 1, 2025, View Source [SID1234651709]). The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 31, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to six individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 23,700 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.